Global Cystic Fibrosis Treatment Market Report and Forecast 2023-2031

Global Cystic Fibrosis Treatment Market Report and Forecast 2023-2031


Global Cystic Fibrosis Treatment Market Outlook


The global market value in 2022 was USD 8.3 billion, driven by the increasing prevalence of the disease and the introduction of new therapies across the globe. The Global Cystic Fibrosis Treatment Market size is anticipated to grow at a CAGR of 13.4% during the forecast period of 2023-2031 to achieve a value of USD 25.7 billion by 2031.

Cystic Fibrosis Market: Introduction


Cystic fibrosis (CF) is a genetic disorder that primarily affects the lungs and digestive system. It causes thick and sticky mucus to build up in the airways and other organs, leading to frequent infections, lung damage, and difficulty in breathing. CF is caused by a mutation in the gene that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein, which regulates the transport of salt and water in and out of cells. There is currently no cure for CF, and treatment aims to manage symptoms and prevent complications.

CF is a rare disease, affecting approximately 70,000 people worldwide. It is most commonly diagnosed in infancy or early childhood, but can also be diagnosed in adults. The incidence of CF varies depending on the population, with higher rates in people of European descent. Treatment options for CF include airway clearance techniques, antibiotics to treat infections, and medications that target specific symptoms of the disease. In severe cases, lung transplantation may be necessary. Research is ongoing to develop new therapies and improve the quality of life for people with CF.

Key Trends in the Cystic Fibrosis Market


Some key trends in the cystic fibrosis market include:
  • Emergence of new treatments: With ongoing research and development in the field, new and more effective treatments for cystic fibrosis are being developed. These treatments are aimed at addressing the underlying cause of the disease, rather than just treating the symptoms.
  • Increased focus on personalized medicine: As understanding of the genetics of cystic fibrosis improves, there is a growing focus on personalized medicine. This involves tailoring treatment plans to the specific genetic mutations of individual patients, in order to achieve the best possible outcomes.
  • Rising prevalence of cystic fibrosis: While cystic fibrosis is a relatively rare disease, its prevalence is increasing globally. This is in part due to improved diagnosis and screening, which has allowed more people to be identified and treated.
  • Growing awareness and advocacy: There is a growing awareness of cystic fibrosis among the general public, which has helped to drive increased funding for research and development, as well as better access to care for patients.
  • Advancements in gene therapy: Gene therapy has shown promise as a potential treatment for cystic fibrosis, and ongoing research in this area is expected to yield new and more effective therapies in the coming years.

Cystic Fibrosis Market Segmentation


Market Breakup by Treatment Methods
  • Medications
  • Devices
Market Breakup by Drug Class
  • Cystic Fibrosis Transmembrane Conductance Regulator (CFTR)
  • Bronchodilators
  • Mucolytic
  • Pancreatic Enzyme Supplement
  • Others
Market Breakup by Drug Molecule Type
  • Small Molecules
  • Biologics
Market Breakup by Route of Administration
  • Oral
  • Parentals
  • Others
Market Breakup by Treatment Channel
  • Public
  • Private
Market Breakup by Distribution Channel
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • Others
Cystic Fibrosis Market by Region
  • North America
  • United States of America
  • Canada
  • Europe
  • United Kingdom
  • Germany
  • France
  • Italy
  • Others
  • Asia Pacific
  • China
  • Japan
  • India
  • ASEAN
  • Australia
  • Others
  • Latin America
  • Brazil
  • Argentina
  • Mexico
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Nigeria
  • South Africa
  • Others

Cystic Fibrosis Market Scenario


Cystic fibrosis is a genetic disorder that affects the respiratory, digestive, and reproductive systems. It is caused by a mutation in the CFTR gene, which leads to the production of thick and sticky mucus in the body. This mucus can cause blockages in the lungs, pancreas, and other organs, leading to serious health problems such as lung infections, malnutrition, and infertility.

The market for cystic fibrosis treatments has been rapidly growing due to the increasing prevalence of the disease and the introduction of new therapies. In recent years, several new drugs have been approved for the treatment of cystic fibrosis, including CFTR modulators, which target the underlying genetic defect and have been shown to improve lung function and reduce the frequency of exacerbations.

The market is also seeing a shift towards personalized medicine, with the development of treatments that target specific mutations in the CFTR gene. This approach has the potential to improve treatment outcomes and reduce healthcare costs by ensuring that patients receive the most effective therapies for their specific genetic mutations.

Overall, the cystic fibrosis market is expected to continue to grow in the coming years, driven by ongoing research and development efforts, increasing awareness of the disease, and the growing demand for personalized treatment options.

Cystic Fibrosis Market: Competitor Landscape


The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the cystic fibrosis market are as follows:
  • AbbVie Inc.
  • Allergan
  • Chiesi Farmaceutici SpA
  • F. Hoffmann-La Roche Ltd.
  • Gilead Sciences
  • Novartis AG
  • Pharmaxis Ltd.
  • PTC Therapeutics
  • Vertex Pharmaceuticals
  • Demegen, Inc.
  • Mor Research Applications
  • Alaxia
  • Alcresta Therapeutics, Inc.
  • AstraZeneca
  • Genentech, Inc.
  • Pfizer Inc.
  • Mylan N.V.
  • Alcresta Therapeutics, Inc.
  • Teva Pharmaceutical Industries Ltd
  • Bayer AG
*Please Note:* The report will be completed in 7 business days after order confirmation


1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Cystic Fibrosis Disease Overview
3.1 Guidelines and Stages
3.2 Pathophysiology
3.3 Screening and Diagnosis
3.4 Treatment Pathway
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Cystic Fibrosis Epidemiology Analysis
5.1 Epidemiology Overview (2016-2031)
5.2 North America Cystic Fibrosis Epidemiology (2016-2031)
5.3 Europe Cystic Fibrosis Epidemiology (2016-2031)
5.4 Asia-Pacific Cystic Fibrosis Epidemiology (2016-2031)
5.5 Latin America Cystic Fibrosis Epidemiology (2016-2031)
5.6 Middle East & Africa Cystic Fibrosis Epidemiology (2016-2031)
6 Global Cystic Fibrosis Market Overview
6.1 Global Cystic Fibrosis Market Historical Value (2016-2022)
6.2 Global Cystic Fibrosis Market Forecast Value (2023-2031)
7 Global Cystic Fibrosis Market Landscape
7.1 Cystic Fibrosis: Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Cystic Fibrosis: Product Landscape
7.2.1 Analysis by Treatment Methods
7.2.2 Analysis by Drug Class
7.2.3 Analysis by Molecule Type
7.2.4 Analysis by Route of Administration
7.2.5 Analysis by Distribution Channel
8 Cystic Fibrosis Challenges and Unmet Needs
8.1 Treatment Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps
9 Cost of Treatment
10 Global Cystic Fibrosis Market Dynamics
10.1 Market Drivers and Constraints
10.2 SWOT Analysis
10.3 Porter’s Five Forces Model
10.4 Key Demand Indicators
10.5 Key Price Indicators
10.6 Industry Events, Initiatives, and Trends
10.7 Value Chain Analysis
11 Global Cystic Fibrosis Market Segmentation
11.1 Global Cystic Fibrosis Market by Treatment Methods
11.1.1 Market Overview
11.1.2 Medications
11.1.3 Devices
11.2 Global Cystic Fibrosis Market by Drug Class
11.2.1 Market Overview
11.2.2 Cystic Fibrosis Transmembrane Conductance Regulator (CFTR)
11.2.3 Bronchodilators
11.2.4 Mucolytic
11.2.5 Pancreatic Enzyme Supplement
11.2.6 Others
11.3 Global Cystic Fibrosis Market by Drug Molecule Type
11.3.1 Market Overview
11.3.2 Small Molecules
11.3.3 Biologics
11.4 Global Cystic Fibrosis Market by Route of Administration
11.4.1 Market Overview
11.4.2 Oral
11.4.3 Parentals
11.4.4 Others
11.5 Global Cystic Fibrosis Market by Treatment Channel
11.5.1 Market Overview
11.5.2 Public
11.5.3 Private
11.6 Global Cystic Fibrosis Market by Distribution Channel
11.6.1 Market Overview
11.6.2 Hospital Pharmacy
11.6.3 Retail Pharmacy
11.6.4 Online Pharmacy
11.6.5 Others
11.7 Global Cystic Fibrosis Market by Region
11.7.1 Market Overview
11.7.2 North America
11.7.3 Europe
11.7.4 Asia Pacific
11.7.5 Latin America
11.7.6 Middle East and Africa
12 North America Cystic Fibrosis Market
12.1 Market Share by Country
12.2 United States of America
12.3 Canada
13 Europe Cystic Fibrosis Market
13.1 Market Share by Country
13.2 United Kingdom
13.3 Germany
13.4 France
13.5 Italy
13.6 Others
14 Asia Pacific Cystic Fibrosis Market
14.1 Market Share by Country
14.2 China
14.3 Japan
14.4 India
14.5 ASEAN
14.6 Australia
14.7 Others
15 Latin America Cystic Fibrosis Market
15.1 Market Share by Country
15.2 Brazil
15.3 Argentina
15.4 Mexico
15.5 Others
16 Middle East and Africa Cystic Fibrosis Market
16.1 Market Share by Country
16.2 Saudi Arabia
16.3 United Arab Emirates
16.4 Nigeria
16.5 South Africa
16.6 Others
17 Regulatory Framework
17.1 Regulatory Overview
17.1.1 US FDA
17.1.2 EU EMA
17.1.3 INDIA CDSCO
17.1.4 JAPAN PMDA
17.1.5 Others
18 Patent Analysis
18.1 Analysis by Type of Patent
18.2 Analysis by Publication year
18.3 Analysis by Issuing Authority
18.4 Analysis by Patent Age
18.5 Analysis by CPC Analysis
18.6 Analysis by Patent Valuation
18.7 Analysis by Key Players
19 Grants Analysis
19.1 Analysis by year
19.2 Analysis by Amount Awarded
19.3 Analysis by Issuing Authority
19.4 Analysis by Grant Application
19.5 Analysis by Funding Institute
19.6 Analysis by NIH Departments
19.7 Analysis by Recipient Organization
20 Clinical Trials Analysis
20.1 Analysis by Trial Registration Year
20.2 Analysis by Trial Status
20.3 Analysis by Trial Phase
20.4 Analysis by Therapeutic Area
20.5 Analysis by Geography
21 Funding and Investment Analysis
21.1 Analysis by Funding Instances
21.2 Analysis by Type of Funding
21.3 Analysis by Funding Amount
21.4 Analysis by Leading Players
21.5 Analysis by Leading Investors
21.6 Analysis by Geography
22 Partnership and Collaborations Analysis
22.1 Analysis by Partnership Instances
22.2 Analysis by Type of Partnership
22.3 Analysis by Leading Players
22.4 Analysis by Geography
23 Supplier Landscape
23.1 AbbVie Inc.
23.1.1 Financial Analysis
23.1.2 Product Portfolio
23.1.3 Demographic Reach and Achievements
23.1.4 Mergers and Acquisitions
23.1.5 Certifications
23.2 Allergan
23.2.1 Financial Analysis
23.2.2 Product Portfolio
23.2.3 Demographic Reach and Achievements
23.2.4 Mergers and Acquisitions
23.2.5 Certifications
23.3 Chiesi Farmaceutici SpA
23.3.1 Financial Analysis
23.3.2 Product Portfolio
23.3.3 Demographic Reach and Achievements
23.3.4 Mergers and Acquisitions
23.3.5 Certifications
23.4 F. Hoffmann-La Roche Ltd.
23.4.1 Financial Analysis
23.4.2 Product Portfolio
23.4.3 Demographic Reach and Achievements
23.4.4 Mergers and Acquisitions
23.4.5 Certifications
23.5 Gilead Sciences
23.5.1 Financial Analysis
23.5.2 Product Portfolio
23.5.3 Demographic Reach and Achievements
23.5.4 Mergers and Acquisitions
23.5.5 Certifications
23.6 Novartis AG
23.6.1 Financial Analysis
23.6.2 Product Portfolio
23.6.3 Demographic Reach and Achievements
23.6.4 Mergers and Acquisitions
23.6.5 Certifications
23.7 Pharmaxis Ltd.
23.7.1 Financial Analysis
23.7.2 Product Portfolio
23.7.3 Demographic Reach and Achievements
23.7.4 Mergers and Acquisitions
23.7.5 Certifications
23.8 PTC Therapeutics
23.8.1 Financial Analysis
23.8.2 Product Portfolio
23.8.3 Demographic Reach and Achievements
23.8.4 Mergers and Acquisitions
23.8.5 Certifications
23.9 Vertex Pharmaceuticals
23.9.1 Financial Analysis
23.9.2 Product Portfolio
23.9.3 Demographic Reach and Achievements
23.9.4 Mergers and Acquisitions
23.9.5 Certifications
23.10 Demegen, Inc.
23.10.1 Financial Analysis
23.10.2 Product Portfolio
23.10.3 Demographic Reach and Achievements
23.10.4 Mergers and Acquisitions
23.10.5 Certifications
23.11 Mor Research Applications
23.11.1 Financial Analysis
23.11.2 Product Portfolio
23.11.3 Demographic Reach and Achievements
23.11.4 Mergers and Acquisitions
23.11.5 Certifications
23.12 Alaxia
23.12.1 Financial Analysis
23.12.2 Product Portfolio
23.12.3 Demographic Reach and Achievements
23.12.4 Mergers and Acquisitions
23.12.5 Certifications
23.13 Alcresta Therapeutics, Inc.
23.13.1 Financial Analysis
23.13.2 Product Portfolio
23.13.3 Demographic Reach and Achievements
23.13.4 Mergers and Acquisitions
23.13.5 Certifications
23.14 AstraZeneca
23.14.1 Financial Analysis
23.14.2 Product Portfolio
23.14.3 Demographic Reach and Achievements
23.14.4 Mergers and Acquisitions
23.14.5 Certifications
23.15 Genentech, Inc.
23.15.1 Financial Analysis
23.15.2 Product Portfolio
23.15.3 Demographic Reach and Achievements
23.15.4 Mergers and Acquisitions
23.15.5 Certifications
23.16 Pfizer Inc.
23.16.1 Financial Analysis
23.16.2 Product Portfolio
23.16.3 Demographic Reach and Achievements
23.16.4 Mergers and Acquisitions
23.16.5 Certifications
23.17 Mylan N.V.
23.17.1 Financial Analysis
23.17.2 Product Portfolio
23.17.3 Demographic Reach and Achievements
23.17.4 Mergers and Acquisitions
23.17.5 Certifications
23.18 Alcresta Therapeutics, Inc.
23.18.1 Financial Analysis
23.18.2 Product Portfolio
23.18.3 Demographic Reach and Achievements
23.18.4 Mergers and Acquisitions
23.18.5 Certifications
23.19 Teva Pharmaceutical Industries Ltd
23.19.1 Financial Analysis
23.19.2 Product Portfolio
23.19.3 Demographic Reach and Achievements
23.19.4 Mergers and Acquisitions
23.19.5 Certifications
23.20 Bayer AG
23.20.1 Financial Analysis
23.20.2 Product Portfolio
23.20.3 Demographic Reach and Achievements
23.20.4 Mergers and Acquisitions
23.20.5 Certifications
24 Cystic Fibrosis Market- Distribution Model (Additional Insight)
24.1 Overview
24.2 Potential Distributors
24.3 Key Parameters for Distribution Partner Assessment
25 Key Opinion Leaders (KOL) Insights (Additional Insight)
26 Company Competitiveness Analysis (Additional Insight)
26.1 Very Small Companies
26.2 Small Companies
26.3 Mid-Sized Companies
26.4 Large Companies
26.5 Very Large Companies
27 Payment Methods (Additional Insight)
27.1 Government Funded
27.2 Private Insurance
27.3 Out-of-Pocket

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings